• Adenovirus Service • AAV Service • Lentivirus Service • Retrovirus Service
WEE1inhibitors were long hailed as a precision weapon againstTP53-mutant malignancies. Because these cancer cells rely heavily on WEE1 to preserve their G2 checkpoint, blocking WEE1 forces them into premature mitosis with unresolved DNA damage, triggering catastrophic cell death. While clinical trials demonstrated clear therapeutic efficacy, severe adverse effects forced multiple studies to halt—with the mechanistic source of this toxicity remaining elusive.
Antibody-drug conjugates (ADCs)have emerged as a cornerstone of precision oncology; however, marked heterogeneity in clinical response remains a major hurdle, and the underlying biological determinants are still poorly understood.
Targeting microglia withadeno-associated viruses (AAVs)has long posed significant challenges due to low transduction efficiency, off-target expression, and inconsistent payload performance.
Prostate cancer is one of the most common malignancies among men. Its incidence has long ranked among the highest for male cancers in Europe and North America. In patients with early-stage or locally advanced disease, the androgen receptor (AR) is a central driver of tumor growth and the principal target of endocrine therapy. However, a substantial proportion of patients gradually become unresponsive during treatment. Their tumors may lose their dependence on AR signaling and transition toward a more aggressive state known as neuroendocrine prostate cancer. Once this transformation occurs, the disease generally responds poorly to existing therapies, metastasizes more rapidly, and is associated with markedly shorter survival. For decades, scientists have sought to understand how prostate cancer undergoes this change in identity.
A research team at the University of California, Los Angeles (UCLA) has engineered a novel class of immune cells capable of attacking atherosclerotic plaques—the fatty deposits within arterial walls that drive the majority of heart attacks and strokes. These engineered cells exert their therapeutic effect by recognizing three distinct pathogenic cell populations within the plaque microenvironment. The findings were published in the journal Circulation Research.
Recently, researchers published a study entitled “Mutant KRAS-m6A Epitranscriptome Axis Promotes Colorectal Cancer and Is a Therapeutic Target.” The study found thatKRASmutations, which occur in approximately 40%–50% of patients with colorectal cancer (CRC), act as driver mutations that mediate aberrant epitranscriptomic remodeling. In clinical samples from patients with CRC, mutant KRAS was associated with elevated levels of mRNA N6-methyladenosine (m6A) modification. Similarly, m6A levels were significantly increased in mutant KRAS cells and mice compared with their wild-type KRAS counterparts in isogenic CRC cell lines and animal models.
Unexplained recurrent spontaneous abortion (URSA) is a common early-pregnancy disorder that seriously affects reproductive health, yet its pathogenesis remains poorly understood. Recently, researchers published a study entitled “NSUN2-Mediated m5C Modification of TGFB1 in Trophoblasts Remodels Macrophage Function to Prevent URSA.” The study revealed for the first time thatNOP2/Sun RNA methyltransferase 2 (NSUN2), an RNA 5-methylcytosine (m5C) methyltransferase, plays a previously unrecognized role in protecting pregnancy by enabling trophoblasts to regulate macrophage function.
Immune checkpointtherapy has transformed the treatment landscape for solid tumors over the past decade. Inhibitors targetingPD-1,PD-L1, andCTLA-4have enabled some patients with advanced cancer to achieve long-term survival. However, substantial limitations remain: only approximately 20%–30% of patients with solid tumors derive significant clinical benefit from these therapies. Most tumors establish a highly immunosuppressive tumor microenvironment that prevents immune cells from infiltrating the tumor or impairs their cytotoxic activity even after they arrive.
The efficacy of cancer immunotherapy is often compromised by low tumor immunogenicity and an immunosuppressive tumor microenvironment (TME), a phenomenon partly driven by the reprogramming of adenosine metabolism within tumors.
CAR T-celltherapy genetically modifies a patient’s own immune cells to recognize and attack cancer. Although the approach has shown tremendous promise, particularly in blood cancers, its reach remains limited. According to a recent analysis, only about 4% of patients with advanced or metastatic cancer in the United States are currently eligible for CAR T-cell therapy, and closer to 3% are likely to benefit.
